Author

Jaroslaw Kierkus

CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

Jaroslaw Kierkus  et al.

European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease
European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease

Jaroslaw Kierkus  et al.

ECCO-ESCP Consensus on Surgery for Crohn’s Disease
ECCO-ESCP Consensus on Surgery for Crohn’s Disease

Jaroslaw Kierkus  et al.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

Jaroslaw Kierkus  et al.

Item 1 - 4 / 4
1